Short Summary
IDT seeks to invalidate Tecan's ’399 NGS patent by alleging obviousness over Iafrate/Kivioja and anticipation/obviousness over Bielas, and requests the PTAB to institute the IPR.
Detailed Summary
Integrated DNA Technologies, Inc. (IDT) has filed a petition for inter partes review of U.S. Patent No. 9,546,399 owned by Tecan Group AG. The petition challenges claims 1‑3, 5‑11, and 14‑17, asserting that the claimed method for detecting duplicate sequencing reads is either obvious when combining the teachings of Iafrate (EX1011) and Kivioja (EX1012) or fully anticipated/obvious over the Bielas publication (EX1013). IDT argues that no secondary considerations support patentability and that discretionary denial under §§325(d) and 314(a) is inappropriate. The Board has not yet ruled on institution, and the proceeding remains at the petition stage.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Integrated DNA Technologies, Inc. et al. vs Tecan Group AG is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Samsung Electronics Co., Ltd. et al.vsHannibal IP LLC
Samsung has filed an IPR petition seeking to invalidate all 19 claims of Hannibal IP’s 5G‑related ’896 patent, arguing that the invention is obvious over Guo, Intel, ZTE and the 5G‑Standard. The petition requests the Board to institute review and cancel the claims.
Klein Tools, Inc.vsMilwaukee Electric Tool Corporation et al.
Klein Tools has filed an IPR petition challenging all 23 claims of Milwaukee Electric Tool’s ’952 container‑assembly patent, arguing obviousness over multiple prior‑art references.
UNION ELECTRIC COMPANY et al.vsMES, Inc.
The USPTO Director denied Union Electric’s request for review of the institution decisions in several IPRs, including the case involving patent 10,596,517. The order affirms the earlier denial of institution.
Amphenol CorporationvsCredo Technology Group Ltd.
Amphenol has filed an IPR petition seeking cancellation of all 20 claims of Credo’s ’898 patent, asserting anticipation and obviousness over four prior‑art references. The petition argues the patent was issued without substantive examination and that discretionary denial is unwarranted.
CSPC Megalith Biopharmaceutical Co., Ltd. et al.vsShanghai Miracogen Inc. et al.
CSPC Megalith Biopharmaceutical Co., Ltd. successfully argued obviousness over Wei, Liu, and Leanna in an IPR proceeding against Shanghai Miracogen Inc. The Board found a reasonable likelihood of success on multiple claims, leading to the institution of the case for trial.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.